Seeking Alpha
View as an RSS Feed

KarinCA  

View KarinCA's Comments BY TICKER:
Latest  |  Highest rated
  • Obama heads to Nike HQ for TPP pitch [View news story]
    What's 10,000 or up to 40,000 new jobs in US when NIKE employs over 1,000,000 indirectly in Asia. Time to focus on a company employing a majority of US workers.

    I'd buy cheap shoes and put expensive orthotics in them before giving NIKE a dime.

    NKE is bad for the US. Too many jobs are drained away and they think 10,000 new ones in US makes up for it? lol I really dislike their labor practices.
    May 9, 2015. 07:27 PM | 2 Likes Like |Link to Comment
  • Interview With Leo Ehrlich, Cellceutix CEO Following Acquisition Of PolyMedix Assets [View article]
    Follow up on assets since acquisition:

    A Randomized, Double-Blind Study Comparing Single-Dose and Short-Course Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin & Skin Structure Infections (ABSSSI)
    http://bit.ly/1DDFuGJ

    ECCMID 2015 Copenhagen, Denmark 25 – 28 April 2015

    Synthetic Novel Host Defense Protein Mimetics for the Treatment of Gram-Negative Bacterial Infections
    http://bit.ly/1z6Dha9

    ECMIID 2015 Copenhagen, Denmark 25 – 28 April 2015

    Brilacidin, Host Defence Peptide mimetic, one of a new class of immunomodulatory ECCMD-0268 agents that can target multiple disease indications
    http://bit.ly/1DDFvum

    2015 ECCMID Copenhagen, Denmark
    Apr 27, 2015. 02:49 PM | Likes Like |Link to Comment
  • Update: Cellceutix's Antibiotic Brilacidin Should Move Share Price Before Kevetrin Or Prurisol [View article]
    A Randomized, Double-Blind Study Comparing Single-Dose and Short-Course Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin & Skin Structure Infections (ABSSSI)
    http://bit.ly/1DDFuGJ

    ECCMID 2015 Copenhagen, Denmark 25 – 28 April 2015


    Synthetic Novel Host Defense Protein Mimetics for the Treatment of Gram-Negative Bacterial Infections
    http://bit.ly/1z6Dha9

    ECMIID 2015 Copenhagen, Denmark 25 – 28 April 2015


    Brilacidin, Host Defence Peptide mimetic, one of a new class of immunomodulatory ECCMD-0268 agents that can target multiple disease indications
    http://bit.ly/1DDFvum

    2015 ECCMID Copenhagen, Denmark
    Apr 27, 2015. 02:11 PM | Likes Like |Link to Comment
  • Tekmira's Ebola vaccine candidate cleared for repeat dosing in Phase 1 study [View news story]
    It's not a vaccine. The Tekmira press release doesn't have the word vaccine in it since it's a therapeutic.

    http://bit.ly/1b5tcjg

    "the partial clinical hold on the company's Investigational New Drug application (IND) for TKM-Ebola has been modified to permit repeat dosing of healthy volunteers at a dose of 0.24 mg/kg/day. The IND remains on partial clinical hold with regard to doses above 0.24 mg/kg/day in healthy volunteers.

    Tekmira plans to resume the TKM-Ebola Phase I clinical trial in the coming weeks. The study is a randomized, single-blind, placebo-controlled study involving repeat dosing of a single cohort of healthy volunteers. Each subject will receive daily doses of 0.24mg/kg of TKM-Ebola or placebo for up to seven days. TKM-Ebola will be administered without steroid pre-medication. Results from the study are expected in the second half of 2015."

    The trial that was authorized to start in Africa on sick patients is a separate issue. I wonder how many patients they've been able to enroll since the epidemic has been subsiding?

    http://bit.ly/1b5teaN

    "TKM-Ebola-Guinea will be evaluated for efficacy in Ebola virus infected patients in Sierra Leone, West Africa. Patient recruitment has been initiated. Patient recruitment has been initiated."
    Apr 16, 2015. 04:01 AM | Likes Like |Link to Comment
  • An Interview With Cellceutix CEO Leo Ehrlich [View article]
    Cellceutix Meeting With FDA to Discuss Phase 2 Clinical Trial for Ulcerative Proctitis Treatment;

    Cellceutix’s Abstract on Kevetrin to Be Presented at ASCO -

    See more at: http://bit.ly/1C8unDH
    Apr 1, 2015. 11:59 AM | Likes Like |Link to Comment
  • Advanced Cell Technology's Intellectual Property Takes A Hit [View article]
    DWD Investing... the following cited work from the first sentence of this article has been discredited:

    Nature article:
    http://bit.ly/1HehbSB

    Scientist Resigns as Stem-Cell Creation Method Is Discredited
    http://bit.ly/1HehcWF

    I'm thinking this article may have been written before the Obokata work was discredited.
    Mar 29, 2015. 08:45 PM | 1 Like Like |Link to Comment
  • Should You Cancel Your Phone, TV And Internet Service Contracts? [View article]
    Elliott... I don't bother going to stores unless I need to physically try something on. There have been times I'll buy two pairs of shoes if unsure of the size and simply return the pair that doesn't fit. I only do this if in a hurry.

    90% of my shopping is done online with the vast majority of it from Amazon. With Amazon prime I get free shipping and most of Amazon prime entertainment for free. All for $99 annually. It's impossible to watch all available to me via Netflix, Amazon Prime and Youtube. The savings is unbelievable. My cost for the setup is a onetime fee for the hotspot app $7.95, Amazon Prime onetime fee of $99, and $8 monthly for Netflix. My Amazon Prime fee has been returned many times over due to the free shipping it gives me. I get daily packages and if I agree to one week shipping instead of 2 day they give me $1 credit in my account.

    I'm looking at a farmer that delivers boxes of vegetables once a week to try and eliminate the grocery store.

    I know many that pay the cell phone company a monthly fee for hotspot usage, but, that's not even needed with an app.

    Just make sure your smart phone is at least 4g for everything to work right. ;)
    Mar 16, 2015. 06:04 PM | 1 Like Like |Link to Comment
  • Should You Cancel Your Phone, TV And Internet Service Contracts? [View article]
    Interestingly, I live between two locations and am in the midst of testing whether or not I can live without my cable service in one of them. I run with my cell phone as a hotspot in my newest location and have found my internet and tv work perfectly fine without cable. My tv is a smart one and I have all the apps I need on it and don't miss cable at all.

    My cell phone plan has unlimited data usage and I use an app for the hotspot usage for free after a one time charge of $7.95. It's working so well off my cell phone I'm seriously considering canceling cable services at my primary location too.

    My second location is up in the mountains with no cable access. I was forced to find another solution and delighted with the results. ;)
    Mar 16, 2015. 02:15 PM | 2 Likes Like |Link to Comment
  • StemCells, Inc., And Neuralstem, Inc.: A Side-By-Side Analysis [View article]
    DWD Investing... I'm thinking you are asking for the CUR ALS trial link. Following is the phase 2 followed by the phase 1

    Neuralstem ALS studies
    http://1.usa.gov/1x1noRu

    “Official Title: A Phase II, Open-label, Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis

    Primary Outcome Measures:
    • To determine the safety of the maximum tolerated dose of human spinal cord-derived neural stem cell transplantation for the treatment of amyotrophic lateral sclerosis (ALS) assessed by the number and severity of adverse events. [ Time Frame: Patients will be followed postoperatively for 24 months. ] [ Designated as safety issue: Yes ]
    The primary objective of the study is to determine the feasibility, safety, toxicity, and maximum tolerated (safe) dose of human spinal cord-derived neural stem cell transplantation for the treatment of amyotrophic lateral sclerosis (ALS).

    Secondary Outcome Measures:
    • To evaluate neurologic deficits post spinal stem cell transplantation therapy. [ Time Frame: Patients will be followed postoperatively for 24 months. ] [ Designated as safety issue: Yes ]
    The secondary objectives of the study are to evaluate spinal stem cell transplantation therapy in this patient population for: 1) attenuation of motor function loss; 2) maintenance of respiratory capacity; 3) stabilization of ALSFRS-R; 4) reduction of spasticity/rigidity if present; and 5) graft survival at autopsy if and when there is mortality.”

    **********

    http://1.usa.gov/1x1nngF

    “Official Title: A Phase l, Open-label, First in Human, Feasibility and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis

    Primary Outcome Measures:
    • The primary objective of this study is to determine the safety of human spinal cord-derived neural stem cell transplantation for the treatment of amyotrophic lateral sclerosis. [ Time Frame: The primary outcome measure will be assessed at study visits pre and post surgery follow-up visits, for a total of 48 months. ] [ Designated as safety issue: Yes ]
    The primary outcome measure is the incidence of adverse events in the study population.”

    See link for long list of Secondary Outcome Measures
    Mar 13, 2015. 11:19 AM | Likes Like |Link to Comment
  • An Interview With Cellceutix CEO Leo Ehrlich [View article]
    sparklshooz... the contract between Cellceutix and Harvard's Dana Farber is what determines what the company says about the Kevetrin phase I trial at this point. Not the FDA.
    Feb 26, 2015. 08:44 PM | 1 Like Like |Link to Comment
  • An Interview With Cellceutix CEO Leo Ehrlich [View article]
    mjl962... congrats on a good trade. You lucked out since biotech's like this are very volatile and it could have gone the other way. Bottom line, you did good. ;)

    Regarding phone numbers for CEO's. Do like I do and go to biotech conventions. You can meet the CEO's after the presentations in the Q&A and get their card. I have a three inch stack of cards I picked up last month at the convention in San Francisco. CEO's were all over the place that week since there were three biotech conventions in town at the same time. I even met some of them on the plane both to and fro. In the hotels, at breakfast. It was amazing how the place was flooded with biotech CEO's. Try it sometime. Do it regularly and you'll actually discover some things you may not have otherwise.

    Share price will do what it does as various catalysts come into play. I just present info for those that might want it.

    Anyway, good luck in all your trades.
    Feb 17, 2015. 10:59 PM | 7 Likes Like |Link to Comment
  • An Interview With Cellceutix CEO Leo Ehrlich [View article]
    Regarded Solutions... Thanks... That's quite the complement coming from you. ;)
    Feb 15, 2015. 07:39 PM | 1 Like Like |Link to Comment
  • An Interview With Cellceutix CEO Leo Ehrlich [View article]
    yunkolicious... That's a good question I'm unable to answer. I've been riding the ups and downs on this one for awhile now since I'm in for a long term play. Overall, it is up. Just pull up a three year weekly chart.
    Feb 12, 2015. 12:04 PM | 3 Likes Like |Link to Comment
  • Cellceutix Undervalued By 90+%; Expect A Short Squeeze Soon [View article]
    dpudvay... posted on company website today.

    $CTIX submitted an application to the NASDAQ Exchange for uplisting... http://bit.ly/1C8rdk5 ...
    Feb 8, 2015. 10:15 PM | 2 Likes Like |Link to Comment
  • Cellceutix Undervalued By 90+%; Expect A Short Squeeze Soon [View article]
    $CTIX submitted an application to the NASDAQ Exchange for uplisting...

    http://bit.ly/1C8rdk5
    Feb 8, 2015. 09:48 PM | 2 Likes Like |Link to Comment
COMMENTS STATS
418 Comments
708 Likes